PHILADELPHIA (AP) _ Spark Therapeutics Inc. (ONCE) on Tuesday reported a loss of $65 million in its third quarter.
On a per-share basis, the Philadelphia-based company said it had a loss of $1.90.
The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.80 per share.
The gene therapy developer posted revenue of $1.9 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $1.4 million.
Spark Therapeutics shares have increased 64 percent since the beginning of the year. The stock has climbed 86 percent in the last 12 months.